Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Dupilumab

Details

Files
Generic Name:
Dupilumab
Project Status:
Active
Therapeutic Area:
Chronic obstructive pulmonary disease (COPD)
Manufacturer:
sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dupixent
Project Line:
Reimbursement Review
Project Number:
SR0870-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) associated with type 2 inflammation.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Add-on maintenance treatment in adult patients with uncontrolled chronic obstructive pulmonary disease (COPD) associated with type 2 inflammation.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open30-Oct-24
Call for patient/clinician input closed20-Dec-24
Submission received11-Dec-24
Submission accepted02-Jan-25
Review initiated03-Jan-25
Draft CADTH review report(s) provided to sponsor for comment21-Mar-25
Deadline for sponsors comments01-Apr-25
CADTH review report(s) and responses to comments provided to sponsor15-May-25
Expert committee meeting (initial)28-May-25
Draft recommendation issued to sponsorJune 09, 2025
To
June 11, 2025
Draft recommendation posted for stakeholder feedback19-Jun-25
End of feedback period04-Jul-25

Files

Patient and Clinician Group input View PDF
Last Updated : January 14, 2025